Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryNov032015	Fate Therapeutics Reports Third Quarter 2015 Financial Results Pluripotent Cell Platform for Generating Off-the-Shelf Cancer Immunotherapies to be Presented at ASH 2015 Annual Meeting First-in-Human Clinical Trial of PROTMUNE™ to Prevent Acute GvHD and Severe Infections Planned for 2016 Reached 70% of Target Enrollment for PROHEMA® PUMA Study SAN Read All »	View HTML Fate Therapeutics Reports Third Quarter 2015 Financial Results 27.9 KB
Toggle SummaryOct292015	Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2015 Financial Results on November 3, 2015 SAN DIEGO, Oct. 29, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders, today announced that the Company will host a conference call and Read All »	View HTML Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2015 Financial Results on November 3, 2015 10.9 KB
Toggle SummaryOct282015	Fate Therapeutics Strengthens Intellectual Property Position With New U.S. Patent Covering Induced Pluripotent Cell Compositions Proprietary Pluripotent Cell Platform Has Broad Applicability for Development of Off-the-Shelf Cancer Immunotherapies Read All »	View HTML Fate Therapeutics Strengthens Intellectual Property Position With New U.S. Patent Covering Induced Pluripotent Cell Compositions 20.8 KB
Toggle SummaryOct122015	Fate Therapeutics Announces Leadership Transition Scott Wolchko , a Fate Founder, to Succeed Christian Weyer as President and CEO Effective December 1, 2015 Additional Leadership Changes Enhance Fate Executive Team SAN DIEGO , Oct. 12, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company engaged in the Read All »	View HTML Fate Therapeutics Announces Leadership Transition 22.8 KB
Toggle SummarySep022015	Fate Therapeutics to Present at September Investor Conferences SAN DIEGO, Sept. 2, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company engaged in the development of programmed cellular immunotherapeutics for the treatment of severe, life-threatening diseases, today announced that Christian Weyer, M.D., M.A.S., President Read All »	View HTML Fate Therapeutics to Present at September Investor Conferences 10.6 KB
Toggle SummaryAug062015	Fate Therapeutics to Present at Upcoming Investor Conferences SAN DIEGO, Aug. 6, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company engaged in the development of programmed cellular immunotherapeutics for the treatment of severe, life-threatening diseases, today announced that management will be presenting at two Read All »	View HTML Fate Therapeutics to Present at Upcoming Investor Conferences 10.6 KB
Toggle SummaryAug052015	Fate Therapeutics Reports Second Quarter 2015 Financial Results Interim Data From PROHEMA® PUMA Study Show Reduction in Severe Infections Across Multiple Pathogen Types First Pediatric Subject Treated in PROHEMA® PROVIDE Study of CNS Cellular Replacement Strategic Research Collaboration Formed With Juno Therapeutics to Identify Small Molecule Read All »	View HTML Fate Therapeutics Reports Second Quarter 2015 Financial Results 38.5 KB
Toggle SummaryJul292015	Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2015 Financial Results on August 5, 2015 SAN DIEGO, July 29, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that the Company will host a conference call and Read All »	View HTML Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2015 Financial Results on August 5, 2015 10.7 KB
Toggle SummaryJul152015	Fate Therapeutics Appoints Dr. Stewart Abbot as Vice President, Translational Research SAN DIEGO, July 15, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, announced today that it has named Dr. Read All »	View HTML Fate Therapeutics Appoints Dr. Stewart Abbot as Vice President, Translational Research 15.1 KB
Toggle SummaryJul142015	Fate Therapeutics and Regents of the University of Minnesota Enter Into Research Collaboration for Translation of Natural Killer Cell Cancer Immunotherapies "Adaptive" Natural Killer Cell Therapeutics to be Advanced as Antibody-Mediated Cancer Therapy Genetically-Engineered Induced Pluripotent Stem Cell-derived Natural Killer Cells to be Developed as Off-the-Shelf Targeted Immunotherapy Fate Therapeutics Holds an Exclusive Option to Secure All Patent Read All »	View HTML Fate Therapeutics and Regents of the University of Minnesota Enter Into Research Collaboration for Translation of Natural Killer Cell Cancer Immunotherapies 23.9 KB

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.